Table 1.
Correlated drugs
| Drug 1 | Drug 2 | p-value | Pearson correlation coefficient |
|---|---|---|---|
| MI-219 | Nutlin-3 | 1.77E−28 | 0.98 |
| Panobinostat (Faridak®) | Vorinostat (Zolinza®) | 2.14E−24 | 0.96 |
| Panobinostat (Faridak®) | Quisinostat | 1.66E−19 | 0.93 |
| Belinostat | Vorinostat (Zolinza®) | 2.05E−18 | 0.92 |
| Belinostat | Panobinostat (Faridak®) | 1.70E−16 | 0.91 |
| Erlotinib (Tarceva®) | Gefitinib (Iressa®) | 3.49E−14 | 0.88 |
| Quisinostat | Vorinostat (Zolinza®) | 1.05E−13 | 0.87 |
| Belinostat | Quisinostat | 8.08E−13 | 0.85 |
| Paclitaxel (Taxol®, OnxalTM) | Docetaxel (Taxotere®) | 4.61E−08 | 0.73 |
| Azacitidine (Vidaza®) | Doxorubicin (Adriamycin®) | 3.77E−07 | 0.7 |
| JNJ-493 | JNJ-707 | 1.39E−05 | 0.62 |
| Decitabine (Dacogen®) | 5-Fluorouracil | 7.77E−05 | 0.58 |
| Decitabine (Dacogen®) | Serdemetan | 1.17E−04 | 0.56 |
| Vandetanib (Zactima®) | Gefitinib (Iressa®) | 1.52E−04 | 0.56 |
| Serdemetan | Tipifarnib (Zarnestra®) | 5.15E−04 | 0.52 |
| Decitabine (Dacogen®) | Lapatinib | 5.29E−04 | 0.52 |
| Veliparib | Serdemetan | 5.47E−04 | 0.51 |
| JNJ-493 | Sunitinib (Sutent®) | 1.37E−03 | 0.48 |
| Veliparib | Decitabine (Dacogen®) | 1.63E−03 | 0.48 |
| Vandetanib (Zactima®) | Erlotinib (Tarceva®) | 1.78E−03 | 0.47 |
| Bortezomib (Velcade®) | Vandetanib (Zactima®) | 1.94E−03 | 0.47 |
| ARQ197 | Docetaxel (Taxotere®) | 1.95E−03 | 0.47 |
| Cisplatin | Sunitinib (Sutent®) | 2.00E−03 | 0.47 |
| JNJ-707 | Brivanib | 2.16E−03 | 0.46 |
| Mitoxantrone (Novantrone®) | JNJ-707 | 2.98E−03 | 0.45 |
| JNJ-707 | Nutlin-3 | 2.87E−03 | −0.45 |
| Cisplatin | Azacitidine (Vidaza®) | 2.16E−04 | −0.55 |
| JNJ-208 | Bortezomib (Velcade®) | 1.96E−06 | −0.66 |
| Cisplatin | Doxorubicin (Adriamycin®) | 5.22E−08 | −0.73 |
Correlation pairs were determined using IC50 values. Statistical thresholds for significance were defined as a p-value <0.01 and a Pearson correlation coefficient above 0.45 or below −0.45